Andrew L. Kung

The paper identifies SMARCAL1 as a key regulator of ALT metabolism and a potential therapeutic target for ALT-positive tumors.

This study shows that PAX3-FOXO1 drives metabolic vulnerabilities in rhabdomyosarcoma, making these cells sensitive to methotrexate.

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.

BATCHIE efficiently identifies effective drug combinations through adaptive experimentation, reducing the number of required experiments while accurately predicting synergies.

The paper identifies treatment-resistant Cancer Stem-Like Cells in breast cancer using single-cell RNA sequencing and validates a drug combination to target them effectively.

This study traces clonal evolution in high-risk neuroblastoma using genomic data from 470 samples, showing metastatic clones can remain dormant and later cause relapses.

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

This study uses geometric network analysis of RNA-Seq data to cluster pediatric sarcoma tumors and identify therapeutic targets through unsupervised methods.

The paper identifies four molecularly distinct glioblastoma subtypes using single-cell protein-activity analysis and shows drug sensitivity is state-dependent.